James Wise

Partner at Balderton Capital

London, England

Overview

James Wise is a Partner at Balderton Capital in London, England, where he specializes in venture capital, private equity, and corporate development. He has served on the boards of companies like SOPHiA GENETICS and Sketchfab, and has made investments in successful startups including Tibber and Kaia Health. Highlights of James Wise's career include his role as a Partner at Balderton Capital and his extensive experience serving on the boards of various successful companies in the tech and healthcare sectors.

Work Experience

Balderton Capital

Partner
2012 - Current
Venture investor and Partner at Balderton, supporting technology start-ups across Europe. Over the last decade we have invested in over 200 businesses, with 22 $B+ outcomes. With $5B in AUM, Balderton is one of the largest and most successful venture funds in Europe, run by entrepreneurs and professional investors, and with a track record of helping build some of Europe's most successful software companies. Lead investments and support our portfolio companies with a particular focus on AI, sustainability and health technologies, with board seats at Sophia Genetics (IPO, Nasdaq), Depop (acq. Etsy), Hubs.com (acq. Protolabs), Sketchfab (acq. Epic), Tibber Energy, GoCardless and others.

Department for Business and Trade

Non Executive Board Member
2023
The Industrial Development Advisory Board (IDAB) advises Ministers on applications for financial support from companies proposing to start or expand capital investment projects in the UK. The main focus of work is overseeing applications from £20M - £1B for investment support in areas such as energy, automative, computing and space infrastructure, though the Board also looks at a range of other projects where Ministers want a commercial view, including development of relevant schemes.

SOPHiA GENETICS

Board Member
2017 - 2021
Advancing data-driven medicine through their world leading genomic software platform. Board member from Series B through to $1.2B Nasdaq IPO ( $SOPH ).

SOPHiA GENETICS is a biotechnology firm that aims to support healthcare professionals by maximizing the power of data-driven medicine.

Raised $265,152,150.00 from Perceptive Advisors.

sophiagenetics.com